#Abstr 0545 GO-BACK Trial Continue vs Withdrawal of GOL in nr-axSpA with inactive disease - Full tx withdrawal associated w/ dx flare - Re-treatment -->rapid clinical response after flare - qMonthly tx --> higher rates of disease activity improvement @RheumNow #ACR22 https://t.co/Z3bhA9D4RQ

P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares 📌Adjusted:⬇️c3, plasma alb & proteinuria levels at BL 📌Non-adj: antidsDNA+, antiSm+ addt'l predictors 🧐p alb & antiSm+ potential predictors? #ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe

Majority of pts withdrawn from IXE to PBO recaptured at least LDA & over half met ID w/ IXE retreatment. This may help us clinically with pts who have treatment interruptions. Abs 0427 #ACR22 @RheumNow https://t.co/m4c3P8l25m https://t.co/iQshG1oq2Y

• Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Ax…

The CONSUL trial by Dr Proft et al. compared impact of CEL+GOL vs. GOL alone on radiographic spinal progression in AS showed no significant difference bet. the 2 grps in mSASSS change after 108 wks. Risk stratify pts who will benefit from tx #ACR22 @RheumNow ABST#0546 #ACRBest https://t.co/jWwX7w85ur

Clinical pearl! First-line tx w/ bio-originator or biosimilar ADA/ETA showed similar effectiveness & safety in long-term cohort of axSpA pts. Response to treatment was also similar between groups. Abs 0431 #ACR22 @RheumNow https://t.co/bGGXk51hIG https://t.co/PSsX3MpSXt

• Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar…

Presenting our last (virtual) #JAKpot poster at #ACR22 1-3 pm ET (7-10 CET) in the RA treatment session. Does anyone know what we will are supposed to do? Stay in front of our computer for 2 hours? @rheum_cat @ProftDr @DrMiniDey @EMEUNET @KragstrupTW https://t.co/uCNMezmJ4V

#ACR22 KNOWLEDGE bowl Dr. Namrata Singh, a judge this year, lead the U Iowa team in their bowl championship 3-peet, 2014, ‘15 & ‘16.

Attending Difficult to treat RA…looking forward to learning new things about this. #Gowithus #ACR22 @IFAiArthritis https://t.co/ChET0ckm0X

@erasmusmcintl @RheumNow Data here from @earlyarthritis (CATCH Canada cohort), similar results. It's not just pain differences - but that's real too. It's lots of things, but whatever the case we ignore sex and gender's impact in RA at our peril. ABST0532 #ACR22 @Janetbirdope @TheLancetRheum @RheumNow https://t.co/27uQmNAlPF

How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines: 💉Pre-vax: 💊csDMARDs - hold time 4 wks 💊bDMARDs -hold time of one dosing interval 💉Post-vax: hold DMARDs for 4 wks #ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC

#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf

• Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Ac…

Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal https://t.co/WdkmkCWClO #ACR22 @RheumNow https://t.co/qlNUFhnuJQ

• An Exploratory Analysis of the Potential Disconnect Between Objective Inflammat…

I've always presumed biopsy-neg GCA just hit skip lesions sections What does RNA-Seq of temporal artery bx tell us? positive bx similar to skip lesions bx neg GCA very different Sometimes it's not just the sampling sometimes it's something different... ABST0486 #ACR22 @RheumNow https://t.co/QITgkZ21sy

Bimekizumab (IL-17A and IL-17F inhibitor) use in non-radiographic AxSpA resulted in rapid improvement of ASAS40 along with reduction in SPARCC MRI SI joint inflammation #Abs0544 @RheumNow #ACR22 https://t.co/pOCg0idGsR